Login
$ETRA
$8.31 +$0.00 (0.0%) After hours

$ETRA SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
12 Nov 2026 10-Q
12 Nov 2026 8-K: Results of Operations and Financial Condition

Ipsoprubart Advancing in Global Registrational Program as Potential First Treatment for sHLH Broadly; Enrollment Completion Expected in Second Half of 2027

10 Nov 2026 Form 4: Gordon Carl L, Director

Bought 49,416 shares ($388K) · Bought 20,000 shares ($165K) · Bought 22,700 shares ($192K)

10 Nov 2026 Form 4: Orbimed Advisors Llc, Director and 2 others

Bought 49,416 shares ($388K) · Bought 20,000 shares ($165K) · Bought 22,700 shares ($192K)

05 Nov 2026 Form 4: Gordon Carl L, Director

Bought 245,113 shares ($1.93M) · Bought 71,367 shares ($537K) · Bought 156,091 shares ($1.14M)

05 Nov 2026 Form 4: Orbimed Advisors Llc, Director and 2 others

Bought 245,113 shares ($1.93M) · Bought 71,367 shares ($537K) · Bought 156,091 shares ($1.14M)

29 Oct 2026 SCHEDULE 13G
28 Sep 2026 SCHEDULE 13G
28 Sep 2026 SCHEDULE 13G
25 Sep 2026 SCHEDULE 13D
23 Sep 2026 Form 4: Orbimed Advisors Llc, Director and 2 others

Received 5,551,837 shares by conversion · Bought 1,333,333 shares ($20M)

23 Sep 2026 Form 4: Gordon Carl L, Director

Received 5,551,837 shares by conversion · Bought 1,333,333 shares ($20M)

21 Sep 2026 Form 3: Westlake BioPartners Fund I, L.p., 10% owner and 3 others

Holds 3,527,136 shares of Common Stock

21 Sep 2026 Form 4: Koe Gary S., Chief Technical Officer

Received 63,656 shares by conversion

21 Sep 2026 Form 4: Stagliano Nancy, Director

Received 255,635 shares by conversion

21 Sep 2026 Form 4: Parry Graham, Chief Scientific Officer

Received 85,504 shares by conversion

21 Sep 2026 Form 4: Dong Quehuong (Kathy), Director

Received 455,484 shares by conversion

21 Sep 2026 S-8
21 Sep 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Other Events

Electra Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify that:

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support